FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104025164> ?p ?o ?g. }

• W2104025164 endingPage "2514" @default.
• W2104025164 startingPage "2507" @default.
• W2104025164 abstract "Objective: In clinical trials, the degree of glucose lowering with sitagliptin has been correlated with the magnitude of dipeptidyl peptidase-4 (DPP-4) inhibition over 24 h. Previous studies evaluating sitagliptin doses ranging from 25 to 200 mg/day demonstrated that the daily dose of 100 mg provided maximal glucose-lowering efficacy for this compound in patients with type 2 diabetes. However, sitagliptin 200 mg once daily provided numerically greater percent plasma DPP-4 inhibition compared with 100 mg once daily. The purpose of this study was to evaluate whether sitagliptin 200 mg once daily provides greater improvement in glycemic efficacy as assessed by weighted mean glucose (WMG) over 24 h relative to sitagliptin 100 mg once daily and to relate the percent DPP-4 inhibition achieved with these doses to any between-treatment differences in glycemic efficacy.Methods: In a double-blind crossover study, patients with type 2 diabetes (fasting plasma glucose [FPG] 130–250 mg/dL) were randomized to one of six treatment sequences over three treatment periods (placebo, sitagliptin 100 mg once daily, or sitagliptin 200 mg once daily). Each of the treatment periods was 7 days in duration, with 28-day washout periods between treatments. After each treatment period, patients underwent blood sampling at various time points over 24 h to determine 24-h WMG. Plasma DPP-4 activity was assessed at trough, 24 h following dosing on day 7; percent DPP-4 inhibition was corrected for sample assay dilution.Results: The 103 randomized patients had a baseline mean FPG of 172 mg/dL. Following a planned interim analysis, the study was stopped because the 24-h WMG values were not different between the sitagliptin doses. Furthermore, a significant carryover effect across periods was observed for FPG; thus, efficacy results from period 1 are presented herein. The 24-h WMG values were significantly (p < 0.01) lower with sitagliptin relative to placebo, but the difference between sitagliptin doses was not significant (p = 0.365). Corrected percent plasma DPP-4 inhibition at trough was not significantly (p = 0.791) different with sitagliptin 200 mg (LS mean [95% CI] 96.9% [90.0, 100.0]) compared with sitagliptin 100 mg (95.6% [88.4, 100.0]). The early termination and the carryover effect described above are limitations to this study.Conclusion: Across sitagliptin doses in this study, the similarity of the 24-h WMG concentrations and the similarity of the corrected DPP-4 inhibition values support prior findings that the maximal glucose-lowering efficacy of sitagliptin is achieved with once-daily dosing of 100 mg.Clinicaltrials.gov: NCT00541229" @default.
• W2104025164 created "2016-06-24" @default.
• W2104025164 creator A5001485785 @default.
• W2104025164 creator A5015472734 @default.
• W2104025164 creator A5017935803 @default.
• W2104025164 creator A5019184747 @default.
• W2104025164 creator A5021432816 @default.
• W2104025164 creator A5022896675 @default.
• W2104025164 creator A5027357772 @default.
• W2104025164 creator A5048351488 @default.
• W2104025164 creator A5060128948 @default.
• W2104025164 creator A5085084466 @default.
• W2104025164 date "2009-08-19" @default.
• W2104025164 modified "2023-10-17" @default.
• W2104025164 title "Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement" @default.
• W2104025164 cites W1986044732 @default.
• W2104025164 cites W1994743271 @default.
• W2104025164 cites W2051462052 @default.
• W2104025164 cites W2054185381 @default.
• W2104025164 cites W2077702349 @default.
• W2104025164 cites W2083473802 @default.
• W2104025164 cites W2085862152 @default.
• W2104025164 cites W2109211688 @default.
• W2104025164 cites W2110590807 @default.
• W2104025164 cites W2123629330 @default.
• W2104025164 cites W2129578585 @default.
• W2104025164 cites W2159205789 @default.
• W2104025164 doi "https://doi.org/10.1185/03007990903209514" @default.
• W2104025164 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19691426" @default.
• W2104025164 hasPublicationYear "2009" @default.
• W2104025164 type Work @default.
• W2104025164 sameAs 2104025164 @default.
• W2104025164 citedByCount "22" @default.
• W2104025164 countsByYear W21040251642012 @default.
• W2104025164 countsByYear W21040251642013 @default.
• W2104025164 countsByYear W21040251642016 @default.
• W2104025164 countsByYear W21040251642017 @default.
• W2104025164 countsByYear W21040251642018 @default.
• W2104025164 countsByYear W21040251642020 @default.
• W2104025164 crossrefType "journal-article" @default.
• W2104025164 hasAuthorship W2104025164A5001485785 @default.
• W2104025164 hasAuthorship W2104025164A5015472734 @default.
• W2104025164 hasAuthorship W2104025164A5017935803 @default.
• W2104025164 hasAuthorship W2104025164A5019184747 @default.
• W2104025164 hasAuthorship W2104025164A5021432816 @default.
• W2104025164 hasAuthorship W2104025164A5022896675 @default.
• W2104025164 hasAuthorship W2104025164A5027357772 @default.
• W2104025164 hasAuthorship W2104025164A5048351488 @default.
• W2104025164 hasAuthorship W2104025164A5060128948 @default.
• W2104025164 hasAuthorship W2104025164A5085084466 @default.
• W2104025164 hasConcept C126322002 @default.
• W2104025164 hasConcept C134018914 @default.
• W2104025164 hasConcept C142724271 @default.
• W2104025164 hasConcept C156490143 @default.
• W2104025164 hasConcept C204787440 @default.
• W2104025164 hasConcept C27081682 @default.
• W2104025164 hasConcept C2777180221 @default.
• W2104025164 hasConcept C2777288759 @default.
• W2104025164 hasConcept C2779284873 @default.
• W2104025164 hasConcept C2780323712 @default.
• W2104025164 hasConcept C2780473172 @default.
• W2104025164 hasConcept C2910260750 @default.
• W2104025164 hasConcept C555293320 @default.
• W2104025164 hasConcept C71924100 @default.
• W2104025164 hasConcept C87813604 @default.
• W2104025164 hasConcept C90924648 @default.
• W2104025164 hasConcept C98274493 @default.
• W2104025164 hasConceptScore W2104025164C126322002 @default.
• W2104025164 hasConceptScore W2104025164C134018914 @default.
• W2104025164 hasConceptScore W2104025164C142724271 @default.
• W2104025164 hasConceptScore W2104025164C156490143 @default.
• W2104025164 hasConceptScore W2104025164C204787440 @default.
• W2104025164 hasConceptScore W2104025164C27081682 @default.
• W2104025164 hasConceptScore W2104025164C2777180221 @default.
• W2104025164 hasConceptScore W2104025164C2777288759 @default.
• W2104025164 hasConceptScore W2104025164C2779284873 @default.
• W2104025164 hasConceptScore W2104025164C2780323712 @default.
• W2104025164 hasConceptScore W2104025164C2780473172 @default.
• W2104025164 hasConceptScore W2104025164C2910260750 @default.
• W2104025164 hasConceptScore W2104025164C555293320 @default.
• W2104025164 hasConceptScore W2104025164C71924100 @default.
• W2104025164 hasConceptScore W2104025164C87813604 @default.
• W2104025164 hasConceptScore W2104025164C90924648 @default.
• W2104025164 hasConceptScore W2104025164C98274493 @default.
• W2104025164 hasIssue "10" @default.
• W2104025164 hasLocation W21040251641 @default.
• W2104025164 hasLocation W21040251642 @default.
• W2104025164 hasOpenAccess W2104025164 @default.
• W2104025164 hasPrimaryLocation W21040251641 @default.
• W2104025164 hasRelatedWork W2141848583 @default.
• W2104025164 hasRelatedWork W2147698512 @default.
• W2104025164 hasRelatedWork W2324643450 @default.
• W2104025164 hasRelatedWork W2341701203 @default.
• W2104025164 hasRelatedWork W2400229282 @default.
• W2104025164 hasRelatedWork W2608558167 @default.
• W2104025164 hasRelatedWork W2743494648 @default.
• W2104025164 hasRelatedWork W2797646286 @default.
• W2104025164 hasRelatedWork W3026628716 @default.

• next